Peritumoral edema status of glioblastoma identifies patients reaching long-term disease control with specific progression patterns after tumor resection and high-dose proton boost.
Dose-escalated radiotherapy
Glioblastoma
Imaging biomarker
Peritumoral edema
Personalized treatment
Proton beam therapy
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
27
06
2021
accepted:
13
08
2021
pubmed:
31
8
2021
medline:
6
11
2021
entrez:
30
8
2021
Statut:
ppublish
Résumé
Glioblastoma peritumoral edema (PE) extent is associated with survival and progression pattern after tumor resection and radiotherapy (RT). To increase tumor control, proton beam was adopted to give high-dose boost (> 90 Gy). However, the correlation between PE extent and prognosis of glioblastoma after postoperative high-dose proton boost (HDPB) therapy stays unknown. We intend to utilize the PE status to classify the survival and progression patterns. Patients receiving HDPB (96.6 GyE) were retrospectively evaluated. Limited peritumoral edema (LPE) was defined as PE extent < 3 cm with a ratio of PE extent to tumor maximum diameter of < 0.75. Extended progressive disease (EPD) was defined as progression of tumors extending > 1 cm from the tumor bed edge. After long-term follow-up (median 88.7, range 63.6-113.8 months) for surviving patients with (n = 13) and without (n = 32) LPE, the median overall survival (OS) and progression-free survival (PFS) were 77.2 vs. 16.7 months (p = 0.004) and 13.6 vs. 8.6 months (p = 0.02), respectively. In multivariate analyses combined with factors of performance, age, tumor maximum diameter, and tumor resection extent, LPE remained a significant factor for favorable OS and PFS. The rates of 5-year complete response, EPD, and distant metastasis with and without LPE were 38.5% vs. 3.2% (p = 0.005), 7.7% vs. 40.6% (p = 0.04), and 0% vs. 34.4% (p = 0.02), respectively. The LPE status effectively identified patients with relative long-term control and specific progression patterns after postoperative HDPB for glioblastoma.
Sections du résumé
BACKGROUND
BACKGROUND
Glioblastoma peritumoral edema (PE) extent is associated with survival and progression pattern after tumor resection and radiotherapy (RT). To increase tumor control, proton beam was adopted to give high-dose boost (> 90 Gy). However, the correlation between PE extent and prognosis of glioblastoma after postoperative high-dose proton boost (HDPB) therapy stays unknown. We intend to utilize the PE status to classify the survival and progression patterns.
METHODS
METHODS
Patients receiving HDPB (96.6 GyE) were retrospectively evaluated. Limited peritumoral edema (LPE) was defined as PE extent < 3 cm with a ratio of PE extent to tumor maximum diameter of < 0.75. Extended progressive disease (EPD) was defined as progression of tumors extending > 1 cm from the tumor bed edge.
RESULTS
RESULTS
After long-term follow-up (median 88.7, range 63.6-113.8 months) for surviving patients with (n = 13) and without (n = 32) LPE, the median overall survival (OS) and progression-free survival (PFS) were 77.2 vs. 16.7 months (p = 0.004) and 13.6 vs. 8.6 months (p = 0.02), respectively. In multivariate analyses combined with factors of performance, age, tumor maximum diameter, and tumor resection extent, LPE remained a significant factor for favorable OS and PFS. The rates of 5-year complete response, EPD, and distant metastasis with and without LPE were 38.5% vs. 3.2% (p = 0.005), 7.7% vs. 40.6% (p = 0.04), and 0% vs. 34.4% (p = 0.02), respectively.
CONCLUSIONS
CONCLUSIONS
The LPE status effectively identified patients with relative long-term control and specific progression patterns after postoperative HDPB for glioblastoma.
Identifiants
pubmed: 34459971
doi: 10.1007/s00432-021-03765-6
pii: 10.1007/s00432-021-03765-6
pmc: PMC8557163
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3503-3516Informations de copyright
© 2021. The Author(s).
Références
Neurosurgery. 2020 Jan 1;86(1):112-121
pubmed: 30799490
World J Surg Oncol. 2015 Mar 11;13:97
pubmed: 25886608
World J Surg Oncol. 2016 Aug 24;14(1):225
pubmed: 27557526
Neurosurg Rev. 2017 Apr;40(2):195-211
pubmed: 27180560
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):425-34
pubmed: 20980108
J Clin Oncol. 2009 Mar 10;27(8):1275-9
pubmed: 19188675
J Neurosurg. 1999 Jan;90(1):72-7
pubmed: 10413158
AJNR Am J Neuroradiol. 2018 Jul;39(7):1201-1207
pubmed: 29748206
J Clin Oncol. 2002 Mar 1;20(5):1375-82
pubmed: 11870182
Brain Tumor Pathol. 2010 Oct;27(2):81-7
pubmed: 21046309
J Neurosurg. 1978 Sep;49(3):333-43
pubmed: 355604
Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):623-30
pubmed: 20888136
Strahlenther Onkol. 2016 Nov;192(11):770-779
pubmed: 27334276
Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):793-800
pubmed: 24495592
Radiother Oncol. 2017 Nov;125(2):248-257
pubmed: 29056290
Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):98-105
pubmed: 19695794
Radiother Oncol. 2016 Jan;118(1):16-23
pubmed: 26678342
J Neurosurg Sci. 2012 Sep;56(3):239-45
pubmed: 22854592
Eur J Neurol. 2009 Jul;16(7):874-8
pubmed: 19473360
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):487-494
pubmed: 28011051
J Neurooncol. 2012 Apr;107(2):359-64
pubmed: 22045118
Radiat Oncol. 2014 Jun 06;9:130
pubmed: 24906388
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Radiat Oncol J. 2019 Mar;37(1):13-21
pubmed: 30947476
Neuro Oncol. 2020 Mar 5;22(3):402-411
pubmed: 31637430
Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):130-6
pubmed: 20399036
J Neurosurg. 2016 Apr;124(4):977-88
pubmed: 26495941
Neuro Oncol. 2015 Nov;17(11):1525-37
pubmed: 26203066
Mol Aspects Med. 2012 Oct-Dec;33(5-6):579-89
pubmed: 22387049
Neuro Oncol. 2014 Sep;16(9):1263-73
pubmed: 24510240
Clin Cancer Res. 2009 Oct 1;15(19):6002-7
pubmed: 19755387
Cancer. 1981 Feb 15;47(4):649-52
pubmed: 6164465
Lancet Oncol. 2005 Dec;6(12):953-60
pubmed: 16321763
Int J Surg. 2014 Dec;12(12):1500-24
pubmed: 25046751
Pract Radiat Oncol. 2015 Jan-Feb;5(1):e9-16
pubmed: 25413424
J Neurooncol. 2016 Oct;130(1):165-170
pubmed: 27535747
Radiother Oncol. 2018 Apr;127(1):108-113
pubmed: 29291951
J Oncol. 2013;2013:690585
pubmed: 24000284
Biomaterials. 2018 Jan;151:38-52
pubmed: 29059540
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
J Clin Neurosci. 2013 Jun;20(6):818-23
pubmed: 23639620
Radiother Oncol. 2018 Nov;129(2):347-351
pubmed: 30236994
J Clin Oncol. 2006 Jun 1;24(16):2563-9
pubmed: 16735709